Business Wire

DEENOVA

Share
Deenova Celebrates a Year of Undisputed Growth With the Latest Award of Piacenza AUSL Public Tender

After successful market entries in Germany, UK and the 3 years of record breaking sales in France, Deenova consolidates its leadership position in Italy with the award of the Piacenza AUSL Public Tender, confirming Deenova’s 100% customer retention rate since 2007 and an undisputed technological leadership in the field of hospital pharmacy automation aimed at improving processes, patient safety and personnel time efficiency, for healthcare institutions.

The public tender named 'telematic restricted procedure for the entrusting of logistics support services and needed medical devices’ includes the Deenova flagship solutions such as Orbit software, D1 All-In-1 Stations, D1 All-In-1 Trolley, but also the All-in-1 cabinets for the handling of not unit dose medications (All-In-1 Meds, All-In-1 Fridge and All-In-1 Narcotics) and D8 RFID technology for medical devices.

"The 6 years tender at Piacenza AUSLGiorgio Pavesi, CEO of Deenova, stated - confirms the complete satisfaction with our automation solutions among the existing customer base. We provide the highest level of safety and efficiency for traceability of medications and medical devices through restless technological development: in Piacenza hospitals we’ll add new solutions to those already used such as Kanban methodology for automatic reordering of low-cost devices and Real Time Location System for traceability of the patient’s path in surgery unit”.

The Piacenza AUSL has around 750 beds in the 4 hospitals of Bobbio, Castel San Giovanni, Fiorenzuola and Piacenza, with 91 operating units, including the Mental Health Centres and the Hospital Pharmacy. During the last X SIFACT Congress "Clinical outcomes: a shared commitment and responsibility" Piacenza AUSL has been awarded as best abstract for the poster "Management of batch in single-dose therapy prepared by Hospital Pharmacy Service for Mental Health Centres". The project introduced Deenova error-free solutions to ensure the complete traceability of unit-dose therapies, favouring therapeutic adherence and clinical risk management. This medication management model can be extended to large-area warehouses for total supply chain traceability.

Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.

Please visit www.deenova.com for additional information on its market leading solutions.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221219005564/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Payments Modernisation: Gap Between Confidence and Readiness Among Industry Leaders Widens, ACI Worldwide Study Finds2.12.2025 08:00:00 CET | Press release

69% of payments executives see their organisations as leaders, yet fewer than half prioritise innovation as legacy systems and internal resistance slow progress Payments leaders remain confident about the pace of industry innovation, but many risk falling behind as expectations accelerate. New global research from ACI Worldwide (NASDAQ: ACIW) and Globant reveals a widening gap between confidence and readiness that could define industry leadership in 2026 and beyond. The report Payments in Transition: Leadership in an era of transformation, based on a survey of 500 industry leaders across North America, Europe, Latin America, Middle East & Africa, and Asia Pacific, shows that while 69% of executives consider their organisations to be payments leaders, fewer than half (44%) say payments innovation is a C-suite priority. This disconnect is driven by barriers that will become increasingly costly in the year ahead. More than half (55%) of executives admit they are not fully using the techno

Oulu Launches Its European Capital of Culture Year with a Three-day Opening Festival2.12.2025 07:00:00 CET | Press release

The Oulu2026 Opening Festival on 16–18 January 2026 transforms the city centre into a vibrant celebration of culture, community and northern creativity. It marks the beginning of a historic year and invites residents, visitors and partners from Finland, Europe and beyond to take part in a unique moment for Oulu and its 39 partner municipalities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201071170/en/ In January, Oulu’s city centre will transform into the Oulu2026 Opening Festival area. Photo: Harri Tarvainen / City of Oulu image bank. “After years of preparation, Oulu2026 is finally here. The Opening Festival gives everyone a chance to be part of something that will only happen once, and it all begins in the heart of Oulu,” says Piia Rantala-Korhonen, CEO of Oulu2026. Almost 200 events, over 20 venues The Opening Festival presents a wide range of art and cultural experiences all over the city centre. From exhibitions

Pre-filled Syringe Presentation of BYOOVIZ®, Samsung Bioepis' Biosimilar to Lucentis (Ranibizumab), Gains European Approval2.12.2025 07:00:00 CET | Press release

European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopts positive opinion for BYOOVIZ® (ranibizumab) pre-filled syringe (PFS)PFS presentation to become available in Europe in the second quarter of 2026, after the full transition of commercial rights from Biogen back to Samsung Bioepis in January 2026 Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for BYOOVIZ® pre-filled syringe (PFS), a biosimilar referencing Lucentis1 (ranibizumab). BYOOVIZ was first approved by the European Commission (EC) in August 2021 as a single use vial for intravitreal use (0.5 mg/0.05 ml) for the treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to diabetic macular oedema (DME), proliferative diabetic retinopathy (PDR), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or

Murata Unveils World’s First 15nF/1.25kV C0G MLCC in 1210-inch Size2.12.2025 03:00:00 CET | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) announces the launch and mass production of its multilayer ceramic capacitor (MLCC) featuring a capacitance of 15nF, a rated voltage of 1.25kV, and C0G characteristics in the compact 1210-inch (3.2mm x 2.5mm) size. This product delivers highly efficient power conversion and stable performance under high-voltage conditions, making it suitable for onboard chargers (OBCs) in electric vehicles (EVs) and power supply circuits in high-performance consumer devices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201104421/en/ [Murata Manufacturing Co., Ltd.] 15nF/1.25kV/C0G MLCC in 1210-inch Size Resonant and snubber circuits are essential for efficient power conversion and suppressing current and voltage peaks. In both circuits, repeated exposure to high voltage and high current can cause even slight changes in component performance, leading to efficiency loss or

With 40% of Agentic AI Projects Predicted to Fail, Leading Software Developer Says Compliance Is the One Place Where Agentic AI Will Thrive2.12.2025 01:01:00 CET | Press release

Ideagen's CEO explains why binary outcomes and high stakes make compliance ideal for autonomous AI The CEO of one of the world’s leading global compliance software developers, Ideagen, has today (December 2, 2025) said compliance represents the one domain where autonomous AI will succeed – despite technology insights company Gartner® warning "… over 40% of agentic AI projects will be canceled by the end of 2027”. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201511477/en/ Ben Dorks, Ideagen CEO Speaking at the launch of their own agentic AI platform Ideagen Mazlan, Ben Dorks said: “Autonomous AI will succeed in compliance because failure is measurable, stakes are high and outcomes are binary. “AI that continuously monitors jurisdictional or industry specific compliance frameworks, detects patterns across thousands of records, raises actions for others to follow, flags gaps before audits, autonomously? That's agentic. It

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye